Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bochum – page 28

1 704 clinical trials in Bochum, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bochum at a glance
1 704
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

1 704 trials in Bochum

Open in trial search

Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Xelafaslatide
  • Sponsor:ONL Therapeutics Inc.

Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Klinikum Der Universitat Munchen AöR

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Busulfan
  • Sponsor:Medizinische Hochschule Hannover

Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Universitaetsklinikum Ulm AöR

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaet Muenster

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Novartis Pharma AG

Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:University Of Cologne

Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 1815368
  • Sponsor:Boehringer Ingelheim International GmbH

Breast cancer+1

Recruiting

Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:Institut Für Frauengesundheit GmbH

Study of ivosidenib maintenance treatment in patients with IDH1-mutated cholangiocarcinoma after standard chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bochum

What the registry says about research in the country

01 Dermatology Research

Clinical trials focusing on skin conditions, including studies for cutaneous lupus erythematosus, hidradenitis suppurativa, and plaque psoriasis. Novel therapeutic approaches are being evaluated to improve treatment outcomes for patients with chronic skin disorders.

  • Cutaneous Lupus Treatment
  • Hidradenitis Suppurativa Management
  • Plaque Psoriasis Therapy

Multiple studies are investigating new medications for moderate to severe cases of these conditions.

02 Oncology Studies

Innovative research in cancer treatment, particularly focusing on colorectal cancer, pancreatic cancer, gastric cancer, and non-small cell lung cancer. These trials are evaluating targeted therapies and combination treatments.

  • Metastatic Colorectal Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Advanced NSCLC

New therapeutic approaches combining immunotherapy with targeted treatments are being studied.

03 Cardiovascular and Metabolic Research

Studies focusing on heart failure prevention and chronic kidney disease management. Research includes innovative combination therapies and preventive approaches for high-risk patients.

  • Heart Failure Prevention
  • Chronic Kidney Disease
  • Post-COVID POTS

Trials are evaluating new treatment combinations to improve patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.